ASCO GU 2025: Optimizing Treatment Selection and Clinical Decision-Making in Advanced RCC

Experts discuss the evolving treatment landscape in advanced renal cell carcinoma (RCC), focusing on optimal treatment selection and sequencing strategies, with insights from recent clinical trial updates presented at ASCO GU 2025 and their potential impact on clinical practice.

EP. 1: Long-Term Outcomes in Advanced RCC: Analyzing 8 Years of CheckMate 214 Data

February 28th 2025

Experts discuss the 8-year follow-up data from the CheckMate 214 trial evaluating nivolumab plus ipilimumab for first-line treatment of advanced renal cell carcinoma (RCC), and how these mature overall survival (OS) data influence the view of nivolumab plus ipilimumab as a frontline option, alongside insights from efficacy, safety, post hoc subgroup analyses (Albiges et al, Eur Urol, 2022), and health-related quality of life (HRQOL) data (Cella et al, J Clin Oncol, 2022).

EP. 2: Optimizing IO-TKI Selection: Patient-Specific Approaches for Optimal Outcomes

February 28th 2025

Experts discuss how emerging novel doublet regimens in the frontline setting for advanced renal cell carcinoma may address current unmet needs, highlighting specific biomarkers, patient populations, and clinical scenarios where these combinations could offer distinct advantages over existing standards like immunotherapy (IO)/IO or established IO/tyrosine kinase inhibitor (TKI) combinations.